Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Labs

This article was originally published in The Gray Sheet

Executive Summary

June 30 petition to FDA requests exemption of triiodothyronine uptake test systems (21 CFR 862.1715) from premarket notification requirements. Interested parties are allowed under Sec. 206 of FDAMA to make such a request, to which the agency must respond by 180 days or the petition is deemed granted. Abbott points to a literature search revealing that the devices, which have been in use for more than 30 years, do not have a significant history of false or misleading claims, nor do they have a significant history of risks associated with their use



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts